CD274 and neoplasm: Atezolizumab (Tecentriq®) is an antibody for the programmed cell death-1 ligand (PD-L1) and it exerts its efficacy by inhibiting the binding of PD-L1 to both the programmed cell death-1 (PD-1) and B7-1 receptors, thereby restoring tumour-specific immunity [10].